Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase IIb study shows the drug can reverse the progression of chronic kidney disease, making it a potential first-in-class treatment.